Pacira BioSciences, Inc. (PCRX) News
Track canonical SquawkNews coverage tagged to PCRX, Pacira BioSciences, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 12 indexed stories across 8 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Pacira BioSciences Price Target Announced at $32.00/Share by Oppenheimer
Ratings actions from Benzinga: GMT) Pacira BioSciences Initiated at Outperform by OppenheimerRatings actions from Benzinga
NEWS | Sep 23, 2026, 10:43 AM UTC
L
Leerink Partners sets Pacira Biosciences price target at $28
Leerink Partners announced a $28.00/share price target for Pacira Biosciences (PCRX).
EQUITY | Sep 09, 2026, 03:31 PM UTC
L
Pacira BioSciences grants inducement awards under Nasdaq Rule 5635(c)(4)
Pacira BioSciences said it granted inducement awards on September 2, 2026 to five new employees, pursuant to Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 09, 2026, 12:03 PM UTC
L
Pacira BioSciences reports inducement grants under Nasdaq Rule 5635(c)(4)
Pacira BioSciences (PCRX) reported inducement grants under Nasdaq listing rule 5635(c)(4).
EQUITY | Sep 09, 2026, 12:00 PM UTC
L
PharmaCorp Rx Inc. Announces Board and Committee Changes
PharmaCorp Rx Inc. Announces Board and Committee Changes
EQUITY | Aug 27, 2026, 11:37 AM UTC
H
Pacira BioSciences Publishes Positive PCRX-201 Data
Pacira BioSciences publishes positive two-year phase 1 data
EQUITY | Aug 06, 2026, 12:00 PM UTC
L
Pacira BioSciences Lowers FY2026 Sales Guidance from $745.000M-$770.000M to $735.000M-$760.000M vs $766.384M Est
Pacira BioSciences (NASDAQ: PCRX ) lowers FY2026 sales outlook from $745.000 million-$770.000 million to $735.000 million-$760.000 million vs $766.384 million estimate.
EARNINGS | Aug 04, 2026, 08:03 PM UTC
L
PCRX - Pacira BioSciences Reports Second Quarter 2026 Financial Results
PCRX - Pacira BioSciences Reports Second Quarter 2026 Financial Results
EARNINGS | Aug 04, 2026, 08:01 PM UTC
L
PharmaCorp Closes Previously Announced Eight-Store Acquisition and Provides Acquisition Pipeline Update
Eight pharmacies acquired at an aggregate
MNA | Jul 06, 2026, 11:30 AM UTC
L
HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $38 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Pacira BioSciences (NASDAQ: PCRX ) with a Buy and maintains $38 price target.
EQUITY | Jul 01, 2026, 12:15 PM UTC
L
Pacira BioSciences Says UnitedHealthcare Now Provides Separate Reimbursement For EXPAREL Across Outpatient Settings, Including Hospital Outp
- Expands Patient Access to Non-Opioid Postsurgical Pain Management Across Outpatient Settings -- BRISBANE, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX ), the industry leader in its c
EQUITY | Jul 01, 2026, 12:02 PM UTC
H
Select Premarket Movers
Upside: -AVAV +35% (earnings, guidance) -VWAV +29% (acquires 51% controlling interest in private Israeli aerospace and defense company Meteor Aerospace for ~$20.4M in stock) -SEDG +11% (solar stock strength following FCC
GEOPOLITICS | Jun 30, 2026, 12:26 PM UTC